A recent study by Sawada et al. [24] in patients with newly-diagnosed impaired glucose metabolism, including both diabetes and impaired glucose tolerance (IGT), accompanied by CAD, has shown favorable effects of 1800 mg of EPA daily on postprandial hyperglycemia, hyperlipidemia, and insulin secretion. The gene discussed is INS; the disease is Hyperglycemia.